News

2022

2021

2020

Aug 09, 2022
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders
Read more
Read more
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders
Aug 09, 2022
Read more
Read more
Jul 06, 2022
Mindset Pharma Receives Allowance for Patent Application Covering its Short-Duration Novel Psychedelic Medications for The Treatment of Central Nervous System Disorders
Read more
Read more
Mindset Pharma Receives Allowance for Patent Application Covering its Short-Duration Novel Psychedelic Medications for The Treatment of Central Nervous System Disorders
Jul 06, 2022
Read more
Read more
Jun 29, 2022
Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation
Read more
Read more
Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation
Jun 29, 2022
Read more
Read more
Jun 22, 2022
Mindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular Profile of MSP-1014 Compared to Psilocybin
Read more
Read more
Mindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular Profile of MSP-1014 Compared to Psilocybin
Jun 22, 2022
Read more
Read more
Jun 10, 2022
Mindset Pharma Receives Notice of Allowance for Patent Application Covering Psilocin Derivatives for the Treatment of Central Nervous System Disorders
Read more
Read more
Mindset Pharma Receives Notice of Allowance for Patent Application Covering Psilocin Derivatives for the Treatment of Central Nervous System Disorders
Jun 10, 2022
Read more
Read more
Jun 07, 2022
Mindset Pharma to Participate in Upcoming Conferences in June 2022
Read more
Read more
Mindset Pharma to Participate in Upcoming Conferences in June 2022
Jun 07, 2022
Read more
Read more
May 12, 2022
Mindset Pharma Progresses Plans for Clinical Trials of its Advanced Pre-Clinical Psychedelic, MSP-1014
Read more
Read more
Mindset Pharma Progresses Plans for Clinical Trials of its Advanced Pre-Clinical Psychedelic, MSP-1014
May 12, 2022
Read more
Read more
May 04, 2022
Mindset Pharma to Participate in Upcoming Conferences in May 2022
Read more
Read more
Mindset Pharma to Participate in Upcoming Conferences in May 2022
May 04, 2022
Read more
Read more
Apr 19, 2022
Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds
Read more
Read more
Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds
Apr 19, 2022
Read more
Read more
Apr 05, 2022
Mindset Pharma to Participate in Upcoming Conferences in April 2022
Read more
Read more
Mindset Pharma to Participate in Upcoming Conferences in April 2022
Apr 05, 2022
Read more
Read more
Mar 17, 2022
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders
Read more
Read more
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders
Mar 17, 2022
Read more
Read more
Mar 03, 2022
Mindset Pharma to Participate in Upcoming Investor Conferences in March 2022
Read more
Read more
Mindset Pharma to Participate in Upcoming Investor Conferences in March 2022
Mar 03, 2022
Read more
Read more
Feb 17, 2022
Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions
Read more
Read more
Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions
Feb 17, 2022
Read more
Read more
Feb 08, 2022
Mindset Pharma Appoints Dr. Fiona Randall as Senior Vice President of External Alliances and Scientific Strategy
Read more
Read more
Mindset Pharma Appoints Dr. Fiona Randall as Senior Vice President of External Alliances and Scientific Strategy
Feb 08, 2022
Read more
Read more
Feb 03, 2022
Mindset Pharma Aims to Treat Broader Addressable Neurology Market by Studying Cognitive Benefits of its “Microdosing” Compounds
Read more
Read more
Mindset Pharma Aims to Treat Broader Addressable Neurology Market by Studying Cognitive Benefits of its “Microdosing” Compounds
Feb 03, 2022
Read more
Read more
Jan 25, 2022
Mindset Pharma Enters Manufacturing Agreement with Leading CDMO to Produce Pharmaceutical Grade Batches of Next-Generation Psilocybin Drug Candidate, MSP-1014
Read more
Read more
Mindset Pharma Enters Manufacturing Agreement with Leading CDMO to Produce Pharmaceutical Grade Batches of Next-Generation Psilocybin Drug Candidate, MSP-1014
Jan 25, 2022
Read more
Read more
Jan 05, 2022
The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines
Read more
Read more
The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines
Jan 05, 2022
Read more
Read more
Jan 04, 2022
Mindset to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022
Read more
Read more
Mindset to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022
Jan 04, 2022
Read more
Read more
Get to know us
Let Us Help You
Join the Conversation
Linkedin Youtube Instagram Twitter Facebook
Subscribe
Get Updates

Copyright © 2022 Mindset Pharma All rights reserved. | Disclaimer & Privacy Policy

Subscribe for latest news